These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 15912558

  • 1. The effect of escitalopram on sleep problems in depressed patients.
    Lader M, Andersen HF, Baekdal T.
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [Abstract] [Full Text] [Related]

  • 2. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M.
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM, Azorin JM, Despiegel N, Verpillat P.
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [Abstract] [Full Text] [Related]

  • 5. The onset of effect for escitalopram and its relevance for the clinical management of depression.
    Wade A, Friis Andersen H.
    Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
    [Abstract] [Full Text] [Related]

  • 6. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S, Baldwin DS, Larsson Lönn S, Boulenger JP.
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

  • 8. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
    Boulenger JP, Hermes A, Huusom AK, Weiller E.
    Curr Med Res Opin; 2010 Mar; 26(3):605-14. PubMed ID: 20067433
    [Abstract] [Full Text] [Related]

  • 9. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 10. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A, Korotzer A, Gommoll C, Li D.
    Depress Anxiety; 2008 Jun; 25(10):854-61. PubMed ID: 18050245
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
    von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hultén A.
    J Clin Psychopharmacol; 2006 Jun; 26(3):311-5. PubMed ID: 16702897
    [Abstract] [Full Text] [Related]

  • 12. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B, Andersen HF, Dolberg OT.
    Depress Anxiety; 2007 Jun; 24(1):53-61. PubMed ID: 16937393
    [Abstract] [Full Text] [Related]

  • 13. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P, Andersen HF, Wade A.
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [Abstract] [Full Text] [Related]

  • 14. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K, Andersen HF, Reines EH.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [Abstract] [Full Text] [Related]

  • 15. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P, Lönn SL, Overø KF.
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B, Moore N, Verdoux H, Auray JP.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [Abstract] [Full Text] [Related]

  • 17. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
    Leinonen E, Niemi H.
    Nord J Psychiatry; 2007 Mar; 61(2):109-14. PubMed ID: 17454725
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC.
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [Abstract] [Full Text] [Related]

  • 19. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP, Tonnoir B, Ménard F, Galinowski A.
    Depress Anxiety; 2007 Oct; 24(5):318-24. PubMed ID: 17041922
    [Abstract] [Full Text] [Related]

  • 20. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
    Pinto C, Trivedi JK, Vankar GK, Sharma PS, Narasimha V.
    J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.